Clinical trials: Cancer: Solid Tumors
Solid Cancers
A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
This is a Phase Ib, open-label, dose-escalation study of MNRP1685A given by intravenous (IV) infusion as therapy for locally advanced or metastatic solid tumors.
- Trial name
- NCT00954642
- Testing
- bevacizumab, MNRP1685A, paclitaxel
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
Solid Tumors
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer…
- Trial name
- NCT07415031
- Testing
- Adagrasib, Pembrolizumab, Cetuximab
- Where
- 101 sites in United States, Australia and 19 more
- Volunteers
- 170 people
- Sponsor
- Mirati Therapeutics Inc.
Solid Tumor
Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors
The purpose of this study is to determine whether the combination of Ulocuplumab and Nivolumab is safe and effective in the treatment of pancreatic cancer and small cell lung cancer.
- Trial name
- CXCessoR4 (NCT02472977)
- Testing
- Ulocuplumab, Nivolumab
- Where
- 7 sites in United States, Finland
- Volunteers
- 61 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors
GenSci139 in Patients With Advanced Solid Tumors
This is a phase I, two-part, multicenter, first-in-human study. The Part 1 study will assess the safety, tolerability, preliminary anti-tumor activities, PK profile, immunogenicity and biomarker of GenSci139 in participants with…
- Trial name
- NCT07230977
- Testing
- GenSci139
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Advanced Solid Tumor
PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates
Study 516-010 is an open-label Phase 1, drug-drug interaction and QTc study evaluating the effect of sitravatinib on probe substrates for CYP450 enzymes and BCRP and P-gp transporters.
- Trial name
- NCT04887194
- Testing
- Sitravatinib, Warfarin, Dextromethorphan
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mirati Therapeutics Inc.
Neoplasms
This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
This study is open to adults with different types of advanced cancer (solid tumors). The purpose of this study is to find out the most suitable dose of BI 907828 (brigimadlin) the participants can tolerate.
- Trial name
- NCT03449381
- Testing
- BI 907828
- Where
- 27 sites in United States, Belgium and 9 more
- Volunteers
- 266 people
- Sponsor
- Boehringer Ingelheim
Solid Tumor, Non-Small Cell Lung Cancer Metastatic
Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK
This study is aimed to determine the maximum tolerated dose of ensartinib, an oral ALK inhibitor in Chinese patients with ALK-positive non-small cell lung cancer
- Trial name
- NCT02959619
- Testing
- Ensartinib
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Advanced Solid Tumors, Lymphoma
KN046 in Subjects With Advanced Solid Tumors and Lymphoma
This is a phase Ia/Ib, open-label, multicenter, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of KN046 in subjects with advanced solid tumors and lymphoma .
- Trial name
- NCT03733951
- Testing
- KN046
- Where
- 13 sites in China
- Volunteers
- 139 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced or Metastatic Solid Tumors
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)
This is a study to assess the pharmacokinetics, safety, and tolerability of pembrolizumab formulated with berahyaluronidase when administered as a SC injection to participants with advanced solid tumors.
- Trial name
- NCT05017012
- Testing
- Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab, Pemetrexed
- Where
- 22 sites in Chile, Hungary and 4 more
- Volunteers
- 142 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumors, Merkel Cell Carcinoma
A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma
To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended Phase 2 dose (RP2D) of FF-10850 (topotecan liposome injection) in patients with advanced solid tumors including…
- Trial name
- NCT04047251
- Testing
- FF-10850 Topotecan Liposome Injection
- Where
- 7 sites in United States
- Volunteers
- 96 people
- Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
Advanced Cancer
Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors
The purpose of this investigational study is to determine the safety and tolerability of oral suberoylanilide hydroxamic acid when administered in combination with standard doses of pemetrexed and cisplatin for the treatment of…
- Trial name
- NCT00106626
- Testing
- vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin
- Volunteers
- 52 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumor
First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors
This study is a Phase 1/2, first-in-human, open-label, dose-escalation, and expansion study designed to characterize the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of IMGC936…
- Trial name
- NCT04622774
- Testing
- IMGC936
- Where
- 13 sites in United States, Italy and 1 more
- Volunteers
- 56 people
- Sponsor
- ImmunoGen, Inc.
Neoplasms
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
This study aims to evaluate the safety and tolerability of RO7673396 in participants with advanced solid tumors harboring RAS mutation(s). This study consists of two stages: Stage 1 (Dose Escalation) and Stage 2 (Dose Expansion).
- Trial name
- NCT06884618
- Testing
- RO7673396
- Where
- 25 sites in United States, Australia and 9 more
- Volunteers
- 405 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor, Adult
A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours
This trial will be a two steps Phase I clinical study in patients with advanced solid tumors with an escalating phase (Step 1) followed by an expansion phase (Step 2) of BI 765063, a monoclonal antibody (mAb) antagonist to signal…
- Trial name
- NCT03990233
- Testing
- BI 765063, BI 754091
- Where
- 8 sites in Belgium, France
- Volunteers
- 100 people
- Sponsor
- OSE Immunotherapeutics
Advanced Solid Tumors
Trial to Study the Safety of Intravenous MNK-010 in Advanced Solid Tumors
This is a multicenter, open-label, dose escalation study of MNK-010 in subjects with advanced solid malignancies who have failed conventional therapy.
- Trial name
- NCT02040558
- Testing
- MNK-010
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Mallinckrodt
Advanced Solid Tumors
Study of AMG 256 in Adult Subjects With Advanced Solid Tumors
To evaluate the safety and tolerability of AMG 256 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
- Trial name
- NCT04362748
- Testing
- AMG 256
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 34 people
- Sponsor
- Amgen
Solid Tumor, Adult
Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors
This trial is a multicenter, single-arm, open design designed to evaluate the safety and tolerability of Autologous Tumor Infiltrating Lymphocyte Injection in the treatment of patients with advanced solid tumors, as well as…
- Conditions
- Solid Tumor, Adult, GT316
- Trial name
- NCT06094426
- Testing
- GT316
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Grit Biotechnology
Advanced Solid and Hematological TP53wt Tumors
Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt
To determine and evaluate a safe and tolerated dose of HDM201 in adult patients with selected advanced tumors characterized by wild-type TP53.
- Trial name
- NCT02143635
- Testing
- HDM201, ancillary treatment
- Where
- 15 sites in United States, France and 6 more
- Volunteers
- 208 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer, Colo-rectal Cancer
Stool Collection Sub-Study of Exact Sciences Protocol 2018-01
The primary objective of this sub-study is to obtain de-identified, clinically characterized, stool specimens from subjects with untreated solid tumors for research use in the development and validation of a stool-based test for…
- Conditions
- Colorectal Cancer, Colo-rectal Cancer, Cancer
- Trial name
- NCT04473625
- Testing
- Stool Sample Collection
- Where
- 12 sites in United States
- Volunteers
- 291 people
- Sponsor
- Exact Sciences Corporation
Solid Tumor
A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety/tolerability, pharmacokinetics, and efficacy of GFS101A in combination with Toripalimab in patients with advanced solid tumors.
- Trial name
- NCT05165849
- Testing
- GFS101A, Toripalimab
- Sponsor
- Zhejiang Genfleet Therapeutics Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.